Research and Markets: A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Marke

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/739347/a_decision_support) has announced the addition of the "A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market" report to their offering.

This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. BioSeeker has applied its unique drug assessment methodology to stratify the leukemia pipeline and discern the level of competition in fine detail.

Major Findings from this report:

  • The identified competitive landscape of leukemia drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing leukemia drugs in 41 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the leukemia drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, TOP2A, MS4A1 and CD33.
  • Eight out of ten drug target strategies in Phase II development are new to leukemia drugs and at the same time the greatest numbers of new target strategies are found in Phase II (34%) and Phase I development (19%).
  • Small molecules, antibodies and proteins are the dominating compound strategies of leukemia drugs, which represent almost 90% of the entire pipeline. Cell therapy based leukemia drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of leukemia drugs.
  • The highest number of described drug target strategies of leukemia drugs belongs to Novartis (9), Pfizer (9) and Bristol-Myers Squibb (8).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty.

For more information visit http://www.researchandmarkets.com/research/739347/a_decision_support

http://twitter.com/#!/researchmarkets



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.